Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29204081 | 0.75 | PKM (0.30) | — | |
| SCHEMBL5894616 | 0.75 | LMNA (0.37) | KDM4ETSHRHTTLMNAMMP2 | |
| SCHEMBL5894605 | 0.74 | TDP1 (0.31) | KDM4ETSHRHTTLMNAMMP2 | |
| SCHEMBL9901185 | 0.74 | KDM4E (0.38) | KDM4EHTTLMNAMAPTALDH1A1 | |
| SCHEMBL747251 | 0.74 | MMP2 (0.35) | KDM4ETSHRHTTLMNAMMP2 | |
| SCHEMBL5894144 | 0.74 | MMP2 (0.35) | KDM4ETSHRHTTLMNAMMP2 | |
| SCHEMBL2361668 | 0.74 | EGFR (0.44) | KDM4E | |
| SCHEMBL5894475 | 0.72 | LMNA (0.38) | KDM4ETSHRHTTLMNAMMP2 | |
| SCHEMBL5894455 | 0.72 | ALDH1A1 (0.41) | KDM4ETSHRHTTLMNACYP3A4 | |
| SCHEMBL1681010 | 0.72 | CCR1 (0.54) | KDM4ETSHRHTTLMNAMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379248-A1 | TRICYCLIC COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002085365-A1 | TRICYCLIC COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | claimed |
| EP-1222186-A2 | CONDENSED NAPHTHYRIDINES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | claimed |
| WO-2001029037-A2 | CONDENSED NAPHTHYRIDINES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-04-26 | — | — | WO | claimed |
| CN-118166457-A | Polyacrylonitrile-based carbon fiber, pre-oxidation method and preparation method thereof | 中复神鹰碳纤维股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118027029-A | Preparation method and application of Anfonafate and analogues thereof | 新疆大学 | 2024-05-14 | — | — | CN | disclosed |
| EP-3496713-B1 | NAPHTHYRIDINE AZAQUINOLONE TO TREAT DISEASES ASSOCIATED WITH DNA REPEAT INSTABILITY | HOSPITAL FOR SICK CHILDREN (CA) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024026500-A2 | INHIBITORS OF PDE11A4 AND METHODS OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11672786-B2 | Methods of treating diseases associated with repeat instability | THE HOSPITAL FOR SICK CHILDREN | 2023-06-13 | — | — | US | disclosed |
| CN-116134026-A | Triazole derivatives and their use as tankyrase inhibitors | 奥斯陆大学国家医院 | 2023-05-16 | — | — | CN | disclosed |
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY INC (US) | 2022-07-14 | — | — | US | disclosed |
| US-20220169648-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-06-02 | — | — | US | disclosed |
| WO-1998039332-A1 | 2-ARYL-NAPHTHYRIDIN-4-ONES AS ANTITUMOR AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-09-11 | — | — | WO | disclosed |
| US-5770590-A | EXCELLENT TACHYKININ RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| EP-0196024-B1 | SUBSTITUTED 1,8-NAPHTHYRIDINONES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1990-11-22 | — | — | EP | disclosed |
| EP-0376870-A1 | A new organosilylpolyphosphoric reagent, its preparation and application to the process of synthesis of 3-carboxyquinolones or azaquinolones and their salts | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1990-07-04 | — | — | EP | disclosed |
| EP-0196024-A1 | Substituted 1,8-naphthyridinones, processes for their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1986-10-01 | — | — | EP | disclosed |
| EP-0196024-A1 | Substituted 1,8-naphthyridinones, processes for their preparation and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1986-10-01 | — | — | EP | disclosed |
| US-4596809-A | Substituted 1,8-naphthyridinones, useful as anti-allergic agents | SCHERING CORPORATION (US) | 1986-06-24 | — | — | US | disclosed |
| US-4596809-A | Substituted 1,8-naphthyridinones, useful as anti-allergic agents | SCHERING CORPORATION (US) | 1986-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220111-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | KDM4E 3184/4885TSHR 1114/4885HTT 4269/4885 |
| US-20220169648-A1 | 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF | NME1, ADORA2A, GPR68 | KDM4E 3184/4885TSHR 1114/4885HTT 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.